Image Credit: STAT News
STAT+: Pharmalittle: We’re reading about J&J and GSK deals, a departing FDA official, and more
J&J agreed to buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of reentry into neuroscience by large drugmakers